Suchergebnisse - (Person:"Bafadhel, Mona")

PubPharm (20)

1

Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19

enthalten in: ResearchSquare.com | 2023

von Cass, S. | Nicolau, D. | Baker, J. | +8

2

Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial

enthalten in: Annals of internal medicine | 2023

von Reis, G. | Dos Santos Moreira Silva, E. | Medeiros Silva, D. | +133

3

Inhaled corticosteroids for the treatment of COVID-19

enthalten in: European respiratory review : an official journal of the European Respiratory Society | 2022

von Bafadhel, M. | Faner, R. | Taillé, C. | +4

4

Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids : a mechanistic analysis

enthalten in: The Lancet. Respiratory medicine | 2022

von Baker, J. | Mahdi, M. | Nicolau, D. | +7

CommentIn: Lancet Respir Med. 2022 Jun;10(6):526-527. - PMID 35397799

5

Chronic obstructive pulmonary disease

enthalten in: Lancet (London, England) | 2022

von Christenson, S. | Smith, B. | Bafadhel, M. | +1

6

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

enthalten in: bioRxiv.org | 2021

von Ramakrishnan, S. | Nicolau, D. | Langford, B. | +21

7

High-dose budesonide for early COVID-19 - Authors' reply

enthalten in: Lancet (London, England) | 2021

von Hobbs, F. | Yu, L. | Saville, B. | +2

CommentOn: Lancet. 2021 Sep 4;398(10303):843-855. - PMID 34388395

8

Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant

enthalten in: BMJ open respiratory research | 2021

von Turnbull, C. | Porter, B. | Evans, S. | +40

9

Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

enthalten in: bioRxiv.org | 2021

von Baker, J. | Mahdi, M. | Nicolau, D. | +7

10

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE) : a randomised, controlled, open-label, adaptive platform trial

enthalten in: Lancet (London, England) | 2021

von Yu, L. | Bafadhel, M. | Dorward, J. | +50

CommentIn: Lancet. 2021 Sep 4;398(10303):818-819. - PMID 34388397